Title: Neoadjuvant chemotherapy with or without PD-1/PD-L1 inhibitors in resectable
esophageal squamous cell carcinoma: a meta-analysis based on randomized controlled trials
Version: 1 Date: 11 May 2025
Reviewer:  Masayuki Watanabe
Reviewer's report:
The authors appropriately revised the manuscript. I apologize for suggesting an incorrect
indication. The study by Zheng et al. was a phase III but not a phase II trial. Please rewrite the
following.
1. Page 2, Abstract, Line 29: phase II to phase III.
2. Page 8, Results, Line 145: phase II to phase III.
Title: Neoadjuvant chemotherapy with or without PD-1/PD-L1 inhibitors in resectable
esophageal squamous cell carcinoma: a meta-analysis based on randomized controlled trials
Version: 1 Date: 11 May 2025
Reviewer:  Masayuki Watanabe
Reviewer's report:
The authors appropriately revised the manuscript. I apologize for suggesting an incorrect
indication. The study by Zheng et al. was a phase III but not a phase II trial. Please rewrite the
following.
1. Page 2, Abstract, Line 29: phase II to phase III.
2. Page 8, Results, Line 145: phase II to phase III.
Please review this paper.
user
Title: Neoadjuvant chemotherapy with or without PD-1/PD-L1 inhibitors in resectable
esophageal squamous cell carcinoma: a meta-analysis based on randomized controlled trials
Version: 1 Date: 11 May 2025
Reviewer:  Masayuki Watanabe
Reviewer's report:
The authors appropriately revised the manuscript. I apologize for suggesting an incorrect
indication. The study by Zheng et al. was a phase III but not a phase II trial. Please rewrite the
following.
1. Page 2, Abstract, Line 29: phase II to phase III.
2. Page 8, Results, Line 145: phase II to phase III.
assistant